Often, when someone receives a challenging diagnosis, it can require them to lean on family and friends for support in new ways.?? ? As we close out #NationalFamilyCaregiversMonth, learn more from the families of Steve and Jennifer who share their experiences helping their loved ones navigate life with rare neurological disorders: https://lnkd.in/eZkqBhBq??
关于我们
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.
- 网站
-
https://www.jazzpharma.com
Jazz Pharmaceuticals的外部链接
- 所属行业
- 制药业
- 规模
- 1,001-5,000 人
- 总部
- Dublin
- 类型
- 上市公司
- 创立
- 2003
- 领域
- Biopharmaceutical 、innovation、research and development 、great place to work、neuroscience 、epilepsy、sleep disorders、oncology和hematology
地点
Jazz Pharmaceuticals员工
动态
-
With our news of the #FDA accelerated approval for our new treatment in biliary tract #cancer (BTC), Jazz continues to expand our oncology portfolio into targeted therapy. Learn more about this significant advancement for BTC patients: bit.ly/3YR9LUI HER2-positive BTC is often associated with poor prognosis, and this milestone means we can now offer an additional chemotherapy-free option to patients with this difficult-to-treat cancer.?
-
-
The FDA has granted accelerated approval of our treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC3+) biliary tract #cancer (BTC), as detected by an FDA-approved test. Learn more about this significant step forward for the BTC community: https://bit.ly/3YR9LUI HER2-positive BTC is often associated with poor prognosis and this milestone means we can now offer an additional chemotherapy-free option to patients with this difficult-to-treat cancer.
-
-
Approximately 50 million people worldwide are impacted by epilepsy – making it one of the most common neurological diseases. Despite its prevalence, serious unmet needs remain for people living with epilepsy syndromes.?? ? This National Epilepsy Awareness Month, learn how we are continuing to work toward redefining possibilities for this patient community: https://lnkd.in/eBAB46kg? ? #NEAM2024?
-
-
More than 210,000 people globally receive a biliary tract cancer (BTC) diagnosis every year, most of whom are diagnosed at an advanced stage.? Elaina Gartner, Vice President Medical, Late-Stage Development, Oncology Clinical Development, details the role of #HER2 in BTC and the importance of testing for HER2 to inform next steps for patients. Read her article here: https://bit.ly/3UTHrjh
-
-
In recognition of #LungCancerAwarenessMonth and #NationalFamilyCaregivingMonth, we’re sharing Ed’s story and his experience with small cell lung cancer (#SCLC). With the support of his daughter and a dedicated care team, Ed continues to demonstrate resilience and courage every day and finds strength in keeping a positive attitude. Read more about Ed’s journey: https://bit.ly/40LSUVQ ? We recognize that those living with SCLC and other difficult diagnoses face many challenges, which is why we’re working to redefine what is possible in the treatment of cancer to improve the lives of patients.?
-
-
Partnering with patient advocacy organizations allows us to hear directly from people impacted by rare cancers, like #biliarytractcancer (BTC), and also facilitates information sharing with patients on new treatments and resources that may help them through their disease journey. Read more about this here: https://lnkd.in/eWHRtGnv As we work to pioneer new pathways in #oncology, we understand that the most valuable insights that inform our research and development come from the people living with these cancers, their loved ones and their physicians.??
-
This #GastricCancerAwarenessMonth, we join the global community in spotlighting the impact of gastric cancer, the fifth most common cancer and the fifth leading cause of cancer-related deaths worldwide. We are advancing oncology research in areas of high unmet need, including a specific type of gastric cancer known as gastroesophageal adenocarcinoma (GEA), which develops in the mucus-secreting glands and accounts for nearly all gastric cancer, and a significant portion of esophageal cancer cases, worldwide. ? Listen to insights from Stefan Faderl, MD, VP, Therapeutic Area Head, Oncology, Clinical Development, on how the anatomy of GEA and a lack of symptoms in the early stages of the disease lead to challenges in both diagnosis and treatment.
-
Jazz announces third quarter 2024 financial results $JAZZ: https://bit.ly/3YY9MX9
-
This week, our teams are in Boston for #PsychCongress2024 where we are presenting eight abstracts from across our sleep portfolio, including the first presentation of top-line results from our Phase 4 trial of adults living with #narcolepsy and idiopathic #hypersomnia. Learn more about the data here: https://bit.ly/3YxidIE For those attending the congress, stop by our booth #632 to learn more about our innovation in sleep medicine and longstanding commitment to supporting the sleep community.
-